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SM5-1 is a humanized mouse monoclonal antibody, targeting an over-expressed membrane protein of
approximately 230 kDa in hepatocellular carcinoma (HCC). SM5-1 can be used for target therapy in
hepatocellular carinoma due to its ability of inhibiting cell growth and inducing apoptosis. However, the
tumor inhibition efﬁcacy of SM5-1 in HCC cancer treatment remains low. In this study, we synthesized
SM5-1-conjugated gold nanoparticles (Au-SM5-1 NPs) and investigated their anticancer efﬁcacy in HCC
both in vitro and in vivo. The tumor inhibition rates of Au-SM5-1 NPs for subcutaneous tumor mice were
40.10% ± 4.34%, 31.37% ± 5.12%, and 30.63% ± 4.87% on day 12, 18, and 24 post-treatment as determined
by bioluminescent intensity. In addition, we investigated the antitumor efﬁcacy of Au-SM5-1 NPs in
orthotopic HCC tumor models. The results showed that the inhibition rates of Au-SM5-1 NPs can reach
up to 39.64% ± 4.87% on day 31 post-treatment determined by the bioluminescent intensity of the
abdomen in tumor-bearing mice. Furthermore, three-dimensional reconstruction results of the ortho-
topic tumor revealed that Au-SM5-1 NPs signiﬁcantly inhibited tumor growth compared with SM5-1
alone. Our results suggested that the developed Au-SM5-1 NPs has great potential as an antibody-
based nano-drug for HCC therapy.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) has become one of the most
leading causes of cancer-related deaths worldwide [1,2]. Although
the treatment of HCC has been improved signiﬁcantly, including
surgery, chemotherapy, and radiation, the survival rates of HCC
patients have not been substantially improved over the last decade
[3,4]. In recent years, tumor-targeted therapy and immunotherapy,lar Imaging of Chinese Acad-
cademy of Sciences, Beijing,
, jie.tian@ia.ac.cn (J. Tian).
Ltd. This is an open access article uincluding antibody therapy, T cell immunotherapy andmacrophage
cell immunotherapy, have been studied extensively [5e9]. Cetux-
imab, an anti-EGFR monoclonal antibody, in phase II studies, has
been used for targeted therapy. But it has shown poor activity
against HCC. Bevacizumab, an anti-VEGF monoclonal antibody, has
been demonstrated efﬁcacy to HCC. However, this efﬁcacy is
limited by high toxicity as bleeding and deep venous thrombosis,
which may worsen the liver function in already cirrhotic patients
[10]. GC33, a humanized antibody against Glypican-3 showed an
inhibition effect on HCC cell proliferation both in vitro and in vivo
[11].
SM5-1 is a monoclonal antibody (mAb) that binds speciﬁcally to
a 230-kDa membrane protein (p230) overexpressed in several
types of cancers, including HCC, melanoma and breast cancer. Re-
ceptor protein p230 was originally discovered in melanoma andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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melanoma [12]. Reinke et al. studied the differential expression of
receptor protein P230 in primary and metastatic melanoma [13].
SM5-1 has been proved to be able to inhibit tumor cell growth or
induce apoptosis. Thus, SM5-1 has been used for diagnosis and
targeted treatment of P230 overexpressing HCC cancer [14e17]. A
subsequent relevant study indicated that the antitumor activity of
SM5-1 is highly related to the expression level of the SM5-1 binding
P230 in the HCC cells [18]. However, the antitumor efﬁciency of
SM5-1 is still poor and needs to be improved urgently.
Antibody conjugated nanoparticle has been widely used for
molecular imaging and enhancing targeted therapy of HCC
[19e23]. Nanoparticles, especially gold nanoparticles (Au NPs),
have been widely explored in biomedical imaging, drug delivery,
diagnostic tests, and tumor treatment [24e26]. Previous studies
have shown that Au NPs-conjugated antibodies can be used for
increasing cytotoxicity and delivery efﬁcacy in several cancer cells
[27,28]. Dechent's group studied the toxicity of Au NPs and
demonstrated a relationship between size and their toxicity
[29,30]. Another exciting application of Au NPs is that they are used
as radiation sensitizers to improve antitumor efﬁcacy [31e33].
In this study, we reported the conjugation of SM5-1 with Au NPs
(Au-SM5-1) and studied its inhibitory effects through in vitro cell
proliferation assays and in vivo animal treatment experiments with
HCC-LM3-fLuc tumor models. Then, adaptive ﬁnite element
method was applied for three-dimensional (3D) reconstruction in
orthotopic HCC xenograft mouse model. Immunohistochemistry
(IHC) experiments were also carried out to demonstrate the inﬂu-
ence of Au-SM5-1 NPs, SM5-1, Au-IgG NPs, IgG and Au NPs on tu-
mor cell proliferation, angiogenesis, and apoptosis. In addition, cell
uptake experiments proved that enhanced clathrin-dependent
endocytosis increased the concentration of Au-SM5-1 NPs. Simul-
taneously, gene expression proﬁles were investigated in the HCC-
LM3-fLuc tumor cells by using gene-chip screening and veriﬁed the
expression of key genes using quantitative reverse transcription
polymerase chain reaction (qRT-PCR).
2. Materials and methods
2.1. Materials
Hydrate (HAuCl4$4H2O), sodium citrate, and sodium borohy-
dride (NaBH4) were obtained from SinoReagent, China. De-ionized
water (DI water, 18.2 MU cm) from the Milli-Q Gradient systemwas
used in all of the preparations. CellTiter96® AQueous One Solution
Cell Proliferation Assay (MTS, batch No. G358A) was purchased
from Promega (Madison,WI, USA). Control IgGwas purchased from
YEASON (Shanghai, China).
2.2. Preparation of Au-SM5-1 NPs
First, citrate-stabilized Au NPs with an average diameter of
about 2.6 nm were prepared as follows: HAuCl4 aqueous solution
(1.0 ml, 1% w/v) was added into DI water (100 ml) with vigorous
stirring for 1 min. Sodium citrate solution (1.0 ml, 1% w/v) was
added to react for 1 min. NaBH4 (1.0 ml, 0.075% w/v) in sodium
citrate (1% w/v) solution was added and continuously stirred for
5 min, and then stored at 4 C [34]. Then, thioglycolic acid was
mixed with citrate-stabilized Au NPs for 12 h to obtain thioglycolic
acid-stabilized Au NPs, and the unreacted portion of thioglycolic
acid was removed using a dialysis method. The antibody SM5-1was
later connect to thioglycolic acid-stabilized Au NPs by the catalysis
of EDC/NHS. Finally, the reaction solution was centrifuged at
14,000 rpm for 25 min, and the supernatant was discarded three
times to obtain pure Au-SM5-1, the ﬁnal product was dissolved inphosphate buffered saline (PBS) for further use. IgG is abbreviation
of Immunoglobulin G which play an important role in the organic
immunity such as antibiosis, antiviral, etc. and it is usually used as
the contrast antibody in the immunotherapy research. Au-IgG NPs
were prepared similarly.
2.3. Characterization of Au-SM5-1 NPs, Au NPs, and SM5-1
The size distribution and zeta potential of Au-SM5-1 NPs were
examined using a 90Plus/BI-MAS DLS analyzer (Brookhaven In-
struments, NY, USA) [35]. Each sample of Au-SM5-1 NPs was
diluted to an appropriate concentration of 1.25 mg/ml with DI
water. Six replicate samples of each type of vesicles were analyzed
at a scatter angle of Q ¼ 90 and a wavelength of 660 nm at room
temperature.
The amount of SM5-1-conjugated Au NPs was quantiﬁed by the
Micro BCA method as described previously [36,37]. Brieﬂy, 500 ml
Micro BCAworking solutionwas added to 500 ml of PBS (pH 7.0), the
dispersion of Au-SM5-1 (1 mg/ml) and Au NPs (1 mg/ml, served as
blank), respectively. After a 60 min incubation period, the absor-
bance was measured at 560 nm using BIO-TEK EL  800 Universal
Microplate Reader. The results were compared to a standard curve
of SM5-1 solution in PBS (pH 7.0) ranging from 0.5 to 20 mg/ml. The
number of antibodies that calculated by Micro BCA experiment
were consistent with the results estimated from the SM5-1 con-
jugated reaction experiment.
The morphologies of Au-SM5-1 NPs and Au NPs were measured
by scanning electron microscopy (SEM, Hitachi S-4300; Hitachi,
Tokyo, Japan) with accelerating voltage of 15 KV. TEM images of Au-
SM5-1 and Au NPs were obtained using a Tecnai Spirit Microscope
with a charge coupled device (CCD) camera operated at 80 KV.
2.4. Cell culture
HCC-LM3-fLuc, HepG2 human HCC cells and human normal
liver cell line HL7702 cells were grown in Dulbecco's Modiﬁed
Eagle's Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) in a humidiﬁed incubator at 37 C in a 5% CO2
atmosphere.
2.5. In vitro cell proliferation assay
HCC-LM3-fLuc cells (1  104) were mixed with seven different
concentrations (n ¼ 3) of Au NPs, SM5-1, IgG, Au-IgG NPs and Au-
SM5-1 NPs for 24 h in ﬁve transparent 96-well plates. Then, cell
viability was measured using a CellTiter 96 cell proliferation assay
kit (MTS, Promega). Brieﬂy, a 20 ml of MTS solution was added to
each well. After incubation for 2 h at 37 C, the absorbance was
measured at 570 nm using a BioTek Synergy HT Universal Micro-
plate Reader. Additionally, seven concentrations (n¼ 3) of Au-SM5-
1 NPs were added into a black 96-well plate to incubate for 24 h.
The bioluminescent intensity was evaluated by adding 20 ml of
luciferin to each well for 3 min at 37 C. The bioluminescent images
were acquired using home-built bioluminescence imaging system
[38e41].
2.6. Cell uptake
HCC-LM3 cells were added into each well of 6-well plates
(1  105 cells/well) and incubated for 24 h at 37 C. Firstly, the cells
were washed carefully with PBS (3) and incubated with different
endocytosis pathway inhibitors such as sodium azide, b-cyclo-
amylose or amiloride for 1 h at 37 C. Then, the cells were treated
with FITC-modiﬁed Au-SM5-1 NPs at a concentration of 2 nM or
FITC-modiﬁed SM5-1 antibody at a concentration of 6 nM for
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gold nanoparticle and three SM5-1 antibodies, detailed in Section
3.1. After incubation, 4 C PBS was added to terminate uptake and
the cells were washed carefully with PBS (3) and digested to
obtain cell suspension. The cells were collected and analyzed using
ﬂow cytometry analysis. Meanwhile, similar experiments were
carried out and the cells were added Au NPs at a concentration of
2 nM. The cells treated with Au NPs were analyzed using induc-
tively coupled plasma mass spectrometry (ICP-MS). All these ex-
periments were performed for three times.
2.7. RNA extraction
HCC-LM3-fLuc cells were added into each well of a 6-well plate
(6  105 cells/well) and incubated with 1 ml of medium overnight.
The cells were then treated with Au NPs, SM5-1, and Au-SM5-1 NPs
at SM5-1 concentration of 0.1 mg/ml (40 ml of Au-SM5-1, 9 ml of
SM5-1, 31 ml of Au NPs, all drug concentrations were 0.1mg/ml) and
incubated for 72 h. Culture media and drugs were refreshed every
24 h, after that drugs at the abovementioned concentrations were
added again into each well. The total RNA was extracted using the
Trizol reagent (Invitrogen, USA) from drug-treated cells according
to themanufacturer's protocol and was puriﬁed by the RNeasymini
kit (QIAGEN, No. 217004). The RNA of each sample was ampliﬁed
and labeled following the manufacturer's protocols (http://www.
affymetrix.com). RNA concentrations were measured with a ND-
1000 spectrophotometer (NanoDrop Technologies), and the qual-
ity (RNA Integrity Number, RIN) was evaluated using the Agilent
2100 Bioanalyzer system (Agilent Biotechnologies) [42,43].
2.8. qRT-PCR
According to the GeneChip results, shown in Supplementary
Information S.1, six complementary DNAs were selected to
perform the following PCR experiments. qRT-PCR was carried out
by ABI SYBR master mix (Applied Biosystems) with gene speciﬁc
primers in a 20 ml of mixture following manufacturers' instructions
on the ABI PRISM 7500 Detection System (Applied Biosystems).
Triplicate reactions were done in three independent experiments.
Expression data were normalized to the geometric mean of
housekeeping gene b-actin to control the variability in expression
levels, and they were analyzed using the 2 DDCT method
described by Livak and Schmittgen [44]. The gene speciﬁc primer
pairs were designed and showed in Table 1.
2.9. Flow cytometry analysis
Flow cytometry analysis was performed to deﬁne the cell cycle
distribution for Au NPs-treated, Au-SM5-1-treated, SM5-1-treated,Table 1
Primer sequence used for qRT-PCR.
Sequence name Sequence (50e30)
p21-RF CGATGGAACTTCGACTTTGTCA
p21-RA GCACAAGGGTACAAGACAGTG
WEE1-RF AGGGAATTTGATGTGCGACAG
WEE1-RA CTTCAAGCTCATAATCACTGGCT
TXNIP-RF ATATGGGTGTGTAGACTACTGGG
TXNIP-RA GACATCCACCAGATCCACTACT
RASA2-RF AGAGGTTCAGGGTAAAGTTCACC
RASA2-RA GAGAAACTGTTGCATAAGGGTCA
NOX1-RF CTGCTTCCTGTGTGTCGCAA
NOX1-RA AGGCAGATCATATAGGCCACC
DUOX2-RF ACGGTGTGTATCAGGCTCTG
DUOX2-RA CACGTCGGAAAGAACATGGTAGand untreated cells. Brieﬂy, cells were harvested by trypsinization,
washed with PBS, and resuspended in 75% ethanol at 4 C for at
least 30 min. Cells (1e2  106) were incubated for 30 min with a
solution containing 50 mg/ml propidium iodide (Sigma), 1 mM
EDTA, 0.1% Triton-X-100 and 100 mg/ml RNase A in PBS for 30min at
37 C [45]. The suspension was passed through a nylon mesh ﬁlter
and analyzed on a ﬂow cytometer (FACscan: Becton Dickinson
Immunocytometry Systems, San Jose, CA) as previously described
[46,47].
2.10. In vivo antitumor studies for subcutaneous tumor models
Female BALB/c nude mice (5 weeks old) were purchased from
the Department of Experimental Animals, Peking University Health
Science Center. All animal experiments were performed in accor-
dance with the guidelines of the Institutional Animal Care and Use
Committee at Peking University. All animal experiment protocols in
this study have been approved by institutional board. The HCC-
LM3-fLuc tumor model was established via subcutaneous injection
of 2  106 HCC-LM3-fLuc tumor cells into the right upper ﬂanks of
BALB/c nude mice. Antitumor activities of Au-SM5-1 NPs, SM5-1
and Au NPs were determined in mice bearing HCCs. The mice
were randomly divided into ﬁve groups and subjected to antitumor
treatment when tumor size reached a volume of about 50 mm3.
Five groups of HCC-LM3 tumor-bearing mice (n ¼ 5 per group)
were treated with PBS, Au NPs (1.17 mg Au NPs per 10 g on day 0, 1,
2, 3), Au-SM5-1 NPs (high, 1.67mg Au-SM5-1 NPs per 10 g on day 0,
1, 2, 3 and 12,13,14,15), Au-SM5-1 NPs (low,1.67mg Au-SM5-1 NPs
per 10 g for four consecutive days), IgG (0.5 mg IgG per 10 g for four
consecutive days), Au-IgG NPs (1.67mg Au-IgG NPs per 10 g for four
consecutive days) or SM5-1 (0.5 mg SM5-1 per 10 g for four
consecutive days) via tail vein injection. Tumor size was measured
with caliper on day 0, 6, 12, 18, 24, 30 after treatment. In addition,
the bioluminescent intensity was calculated to evaluate antitumor
efﬁcacy on day 0, 6, 12, 18, 24, and 30 by bioluminescent imaging
(BLI) of the tumor-bearing mice. Data analysis method was detailed
in Supplementary Information S.4.
2.11. Orthotopic tumor models and three-dimensional
reconstruction of the interior liver tumor
The 18 orthotopic tumor models were established by injecting
2  106 HCC-LM3-fLuc tumor cells into the liver of each BALB/c
nude mouse. The mice were randomized and separated into 6
groups each consisting of 3 mice. One group (control) was injected
i.v. with PBS. The other groups (treatment) were subjected to
antitumor treatment via i.v. injection of Au-SM5-1 NPs, SM5-1 NPs,
Au-IgG NPs, IgG and Au NPs on the 7th day in consideration of
taking the same tumor growth time for the subcutaneous tumor-
bearing mice increased to about 50 mm3. The mice were treated
with four doses given on days 0, 1, 2 and 3. The drug treatment was
repeated for Au-SM5-1 NPs (High) group on days 12, 13, 14 and 15.
The antitumor efﬁcacy was evaluated on day 0, 6, 12, 18, 24 and 30
by acquiring the bioluminescent images of the abdomen of the
orthotopic liver cancer mice and calculated the bioluminescent
intensity. Data acquisition and reconstruction methods were
detailed in Supplementary Information S.5.
2.12. Immunohistochemical examination and analysis
In order to evaluate in vivo tumor proliferation, angiogenesis
and apoptosis histologically, PBS-treated, Au NPs-treated, Au-SM5-
1 NPs (low)-treated, Au-IgG NPs-treated, IgG-treated and SM5-1-
treated tumors in triplicate (13 days post-treatment) were
excised, ﬁxed in formalin, embedded in parafﬁn and cut into 3-mm-
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set of sections was immunostained with puriﬁed anti-MKI67
mouse monoclonal antibody (KI67, Cat. No. TA500265, Zhongshan
Jinqiao Bio-company, Beijing, China) [48]. In situ apoptosis assay
was carried out with the Fluorescein FragEL DNA fragmentation
Detection Kit (Calbiochem, San Diego, CA). Apoptosis was examined
further with an in situ TUNEL assay on HCC-LM3-fLuc xenografted
tumor tissues (TUNEL, QIA39). Apoptotic HCC-LM3-fLuc cells
labeled with ﬂuorescein dye were examined under the ﬂuores-
cence microscope (Leica DFC450C). Three sections of each group
were immunostained, and ﬁve ﬁelds for each section were chosen
randomly for counting the apoptotic cells and proliferation cells
[49,50]. Tumor micro-vessel density (MVD) was quantiﬁed by two
investigators independently in a blinded manner according to the
method reported previously using sections immunostained with
CD31 (BioLegend, San Diego, CA) [51]. Micro-vessel counting was
performed on three separate ﬁelds of each section (three sections
per mouse) chosen randomly at 200 magniﬁcation. Each stained
endothelial cell or cell cluster was counted as one micro-vessel.
Two or more continuous CD31-positive foci in space were also
counted as one micro-vessel. The average number of vessels of
these ﬁelds in three sections was counted for MVD scoring.
2.13. Statistical analysis
Quantitative data were expressed as mean ± SD. Results of two
groups were compared using one-way analysis of variance
(ANOVA) and a Student t-test, and p values <0.05 were believed to
be statistically signiﬁcant. In addition, one-way ANOVA with Dun-
nett's post-test was used to compare cell survival and tumor
growth among three or more groups.
3. Results
3.1. Nanoparticle preparation and characterizations
The Au-SM5-1 NPs were prepared using methods previously
reported [34]. Our methods resulted in desirable characteristics
where 29.7% ± 0.49% (n ¼ 3) SM5-1 conjugation efﬁciency was
achieved. The Au-SM5-1 NPs had a negatively charged surface with
a zeta potential of about30.14mV and had an average diameter of
8.5 nm as measured by 90Plus/BI-MAS DLS analyzer. In addition,
according to the mass of each 5 nm gold nanoparticle and drug
loading efﬁciency [52], about 3 SM5-1 molecules were found to be
conjugated with one gold nanoparticle. Au-SM5-1 NPs, Au-IgG NPs
and Au NPs were examined by TEM and they were found to be
spherical, shown in Fig. 1A (Au NPs) and Fig. 1B (Au-SM5-1 NPs)
respectively. The topography of Au-SM5-1 NPs was measured by
Atomic Force Microscope (Bruker Dimension Edge), shown in
Fig. 1C.
3.2. In vitro proliferation assay and toxicity studies
The cytotoxic activity of various drugs tested on HCC-LM3-fLuc
and HepG2 cell lines were determined (Fig. 2A and B). Fig. 2C dis-
plays the BLI after different drug concentrations of Au-SM5-1 NPs
were added to HCC-LM3-fLuc cells and incubated for 24 h. The data
clearly indicated that Au-SM5-1 NPs inhibited tumor cell prolifer-
ation especially in HCC-LM3-fLuc cells in a dose-dependent
manner. At the concentration of 0.75 mg/ml, HCC-LM3-fLuc cell
survival rates of Au-SM5-1 NPs, Au-IgG NPs, SM5-1, IgG and Au NPs
treated group were 15.4%, 81.7%, 79.8%, 82.9%, 83.6% respectively.
Similarly, at the same concentration, HepG2 cell survival rate of Au-
SM5-1 NPs, Au-IgG NPs, SM5-1, IgG and Au NPs treated group were
42.35%, 80.56%, 80.32%, 80.46%, 81.27% respectively. In a parallelstudy of toxicity using HL7702 cells, the ﬁve drugs induced less
than 20% cell death at the maximal concentration of 0.75 mg/ml.
To validate the toxicity of Au NPs, SM5-1, IgG, Au-IgG NPs and
Au-SM5-1 NPs, four organs including heart, liver, spleen, and kid-
ney of the mice were sectioned on the 17th day post-treatment and
stained with H&E. The results showed no obvious toxicity effects of
Au-SM5-1 NPs in all organs (Fig. 2D). Similarly, no obvious toxicity
effects in the four organs were observed in Au NPs, IgG, SM5-1 and
Au-IgG NPs treated group (not shown).
3.3. Cell uptake
For Au-SM5-1 NPs and SM5-1, cell uptake efﬁciency was deﬁned
as the percentage of SM5-1-FITC amount in the cells versus the
total amount of cells. As the mass of Au NPs can be characterized
according to the size of the nanoparticles [52], we could obtain the
number of nanoparticles per cell derived from the results of the
ICP-MS and calculated the uptake efﬁciency, shown in Fig. 3.
Generally speaking, endocytosis pathways contain macro-
pinocytosis, clathrin-dependent endocytosis, caveolin-dependent
pathways. Thus, internalization pathways of Au-SM5-1 NPs, Au
NPs and SM5-1 could be investigated with speciﬁc endocytosis
inhibitors including sodium azide, b-cycloamylose, amiloride and
the results were shown in Fig. 3. For Au-SM5-1 NPs group, sodium
azide, b-cycloamylose and amiloride can inhibit 39.3%, 11.8% and
22.5% cell uptake per cell respectively (Fig. 3D). For Au NPs group,
the inhibitory rates of sodium azide, b-cycloamylose and amiloride
are 29.2%, 8.3%, 6.3% respectively (Fig. 3E). For antibody SM5-1, all
the three endocytosis pathways are not obvious (Fig. 3C). As shown
in Fig. 3DeF, more Au-SM5-1 NPs could be enclosed into the cells
contrast with Au NPs and antibody SM5-1 without inhibition
agents. According to Fig. 3D and F, the average uptake of SM5-1 per
cell in FITC-Au-SM5-1 is 534 and that in FITC-SM5-1 is 54, so the
uptake fold is 9.89 between these two drugs which is the cause of
different antitumor efﬁcacy of the two drug.
3.4. High DUOX2 expression associated with cell apoptosis
Using the complementary DNA microarray chip, a large-scale
analysis of gene expression was performed during SM5-1 treat-
ment. Target genes, which either up- or down-regulated more than
two-fold at one or more time points, were selected (p < 0.05).
Among the signiﬁcantly changed genes in DNA microarray exper-
iment (S.1) DUOX2, NOX1 (common genes which cause cell
apoptosis for antitumor drugs) are obviously down-regulated genes
which can change the oxidase gene expression level and disturb the
dynamic balance of ROS enzyme system and this phenomenonwas
veriﬁed by qRT-PCR [53e55].
In addition, as an important negative regulatory factor of cell
cycle, gene P21 was up-regulated that was veriﬁed by qRT-PCR too.
Fig. 4 clearly showed that genes DUOX2 and NOX1 were down-
regulated and gene P21 was up-regulated obviously in contrast to
the other three groups.
3.5. Au-SM5-1 NPs induces cell cycle arrest at the G1 checkpoint
To further study Au-SM5-1 NPs -induced cell growth inhibition,
changes in cell cycle progression were monitored using a ﬂow
cytometric analysis. As shown in Fig. 5, it was found that 67.2% of
cells were distributed in the G1 phase after Au-SM5-1 treatment
and 54.7% of cells stayed in the G1 phase after the PBS treatment
(p < 0.05). To a certain degree, Au-SM5-1 NPs led to a decrease in
cell numbers in S phase and G2/M phase. However, SM5-1 and Au
NPs had less inﬂuence on cell cycle distribution. All these results
indicated that Au-SM5-1 NPs induced cell arrest at the G1
Fig. 1.. TEM images of Au NPs (A) and Au-SM5-1 NPs (B), and Atomic Force Microscopic topography of Au-SM5-1 NPs (C).
Fig. 2.. (A) Anti-proliferative effects of Au NPs, SM5-1, Au-IgG NPs, control human IgG and Au-SM5-1 NPs on HCC-LM3 cells. (B) Anti-proliferative effects of Au NPs, SM5-1, and Au-
SM5-1 NPs on HepG2 cells. The viability of cells was examined after 24 h exposure to different vechiles: Au NPs (black), SM5-1 (blue), Au-IgG NPs (green), control human IgG (red)
and Au-SM5-1 NPs (pink) at different concentrations. Data are shown as mean ± SD (n ¼ 5). (C) Bioluminescent image of anti-proliferative effects of Au-SM5-1 NPs on HCC-LM3
cells (n ¼ 3). (D) The slide sections of the heart (a), liver (b), spleen (c), lung (d), and kidney (e) of mice stained with H&E after PBS (control) and Au-SM5-1 NPs treatment. Au NPs
and SM5-1 treated group was similar with the control group which are not shown in this Figure. (**p<0.01; *p<0.05). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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Fig. 3. Effect of endocytosis inhibitors on cellular uptake in resistant HCC-LM3 cells treated with different samples : (A) Au-SM5-1 NPs, (B) Au NPs, (C) SM5-1 antibody. The number
of endocytic particles in every cell: (D) Au-SM5-1 NPs, (E) Au NPs, (F) SM5-1 antibody. (*p<0.05).
X. Ma et al. / Biomaterials 87 (2016) 46e56 51checkpoint, which reduced the number of cells at the next phases of
the cell cycle.
3.6. In vivo antitumor study based on a subcutaneous liver tumor
To evaluate antitumor activities of different drugs, HCC-LM3-
fLuc cells were implanted subcutaneously into mice. The therapy
study was initiated after the tumor size grew to about 50 mm3 by
injecting Au-SM5-1 NPs (high and low), Au-IgG NPs, IgG, Au NPs,
SM5-1, or PBS through the tail veins. Tumor-bearing mice were
treatedwith four doses administered sequentially on day 0,1, 2, and
3. For Au-SM5-1 NPs (high) group, another four doses wereFig. 4. Effects of Au NPs, SM5-1, and Au-SM5-1 NPs inhibition on the relative mRNA
expression of six genes. Relative mRNA expression was measured by qRT-PCR, and the
ampliﬁcation transcripts were quantiﬁed using the relative standard curve and
normalized against subunit b-actin.administered sequentially on day 12, 13, 14, 15. The tumor sizes of
nude mice were then measured with calipers. As shown in Fig. 6,
the tumor sizes increased continuously in six treatment groups at
the duration of the experiment. Notably, on day 12, the tumor sizes
in the Au-SM5-1 NPs (low) treatment group were signiﬁcantly
smaller (p < 0.01) than those in the Au-IgG NPs, IgG, Au NPs, SM5-1,
and PBS groups, and the maximum inhibition rates for treatment
groups were 43.78% ± 3.45%, 13.55% ± 3.15%,
10.33% þ 2.12%,12.00% ± 3.12%, and 16.78% ± 2.36%, respectively.
Afterward, the tumor size difference between the Au-SM5-1 NPs
(low) treated group and the PBS treated group gradually reduced,
however, the tumor sizes of Au-SM5-1 NPs (high) treated group
were obviously smaller than the other ﬁve groups. On day 30, the
inhibition rate was 49.70% for the Au-SM5-1 NPs (high) treated
group but only 18.80% (p < 0.01) for the Au-SM5-1 NPs (low)
treated group.
The baseline BLI signal was also determined on the day before
the ﬁrst drug administration, and then BLI was performed on day 0,
6, 12, 18, 24, and 30 to monitor the tumor growth of the HCC-LM3-
fLuc tumor. The bioluminescent image of HCC-LM3-fLuc cells in the
right ﬂank was acquired at the 8th minute after the intraperitoneal
injection with 200 ml of D-Luciferin (shown in Supplementary
Fig. 4). The tumor size was continuously increasing for PBS, Au
NPs, and SM5-1, IgG, Au-IgG NPs groups, and only a small amount of
inhibition was observed in the Au NPs and SM5-1 treated groups.
As expected, the treatment with Au-SM5-1 NPs (low and high)
clearly showed that the tumor growth rate decreased signiﬁcantly
in vivo on day 12. As determined by BLI, it was found that the
bioluminescent intensity of the Au-SM5-1 NPs (low and high)
treated group was the weakest on the 12th day after drug admin-
istration in contrast to the other three groups. Au-SM5-1 NPs
induced a 40.10%± 4.34%, 31.37%± 5.12%, and 30.63%± 4.87% tumor
growth inhibition rate on day 12, 18, and 24 post-treatment,
respectively. After that, the bioluminescent intensity of the Au-
SM5-1 NPs (low) treatment group was similar to the other
Fig. 5. Effect of Au NPs, SM5-1, Au-SM5-1 NPs on cell cycle progression in HCC-LM3-fLuc cells. Both adherent and non-adherent cells were harvested. Cell cycle distributions were
analyzed by ﬂow cytometry as described in Section 2.9.
Fig. 6. (A) HCC-LM3-fLuc tumor sizes of the nude mice that underwent Au-SM5-1 NPs (low dose, SM5-1: 0.5 mg/ml, mouse blood volume: 2 ml; drug administration at day 0, 1, 2,
3), Au-SM5-1 NPs (high dose, SM5-1: 0.5 mg/ml; drug administration at day 0, 1, 2, 3 and day 12, 13, 14, 15), Au NPs, SM5-1, Au-IgG NPs, control human IgG and PBS treatment.
Volumes of tumors in each group were measured and expressed as mean ± SD, n ¼ 5 per group. (B) The quantiﬁed bioluminescent intensity of the HCC-LM3-fLuc tumors in the
nude mice that underwent Au-SM5-1 NPs (high), Au-SM5-1 NPs (low), Au NPs, SM5-1, Au-IgG NPs, control human IgG and PBS treatment. (C) The mice weight of the ﬁve groups
over time (n ¼ 5 per group). The drug administration intervals are indicated by arrows (day 0, 1, 2, 3). (D) The correlation of bioluminescent intensity and tumor volume of the ﬁve
groups (**p <0.01, mean ± SD, n¼5).
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Fig. 7. (A) Bioluminescent images of orthotopic liver tumor-bearing nude mice that underwent Au-SM5-1 NPs and Au-IgG NPs treatment at day 30. (B) Reconstruction results of a
Au-SM5-1 NPs or Au-IgG NPs treated mouse using the adaptive ﬁnite elements method. (C) Three planes of the reconstructed tumor location for Au-SM5-1 NPs treatment. (D) Three
planes of the reconstructed tumor location for Au-IgG NPs treatment. (E) The quantiﬁed bioluminescent intensity of the orthotopic liver tumor-bearing nude mice that underwent
Au-SM5-1 NPs (high), Au NPs, SM5-1, Au-IgG NPs, control human IgG and PBS treatment. (F) The quantiﬁed bioluminescent intensity of tumors from the six groups on day 30 post-
treatment (**P<0.01,mean ± SD, n ¼ 3).
X. Ma et al. / Biomaterials 87 (2016) 46e56 53groups. However, another round of administration of Au-SM5-1
NPs sustained the inhibition efﬁcacy on tumor and the ﬁnal inhi-
bition rate was 57.6% at day 30. The antitumor efﬁcacy determined
by BLI was consistent with caliper measurements of tumor sizes,
shown in Fig. 6.
Throughout the antitumor study, the weights of Au-SM5-1 NPs
(high), Au-SM5-1 NPs (low), SM5-1, Au-IgG NPs, IgG, Au NPs, and
PBS-treated mice were monitored (Fig. 6D). None of the animals in
the Au-SM5-1 NPs (high and low) treated groups show signiﬁcant
difference from the mice in the other ﬁve groups.
3.7. In vivo antitumor study based on orthotopic liver tumor models
The bioluminescent intensity of each mice could be calculated
using our developed software Windows Molecular Imaging System
(WINMI) [40] and the bioluminescent images of Au-SM5-1 NPs
group and Au-IgG NPs group on 30th day were shown in Fig. 7A
which indicate that Au-SM5-1 NPs can obviously inhibit the tumor
growth than Au-IgG NPs. For Au-SM5-1 NPs group, BLI signals of
the mice increased more slowly and became signiﬁcantly different
from the other ﬁve groups from day 12 post-treatment (shown in
Fig. 7E). There was no obvious difference in BLI signals of the mice
between Au NPs, SM5-1, IgG, Au-IgG NPs and PBS group. According
to calculated BLI signal intensity of the mice abdomen determined
by formula (2), the tumor inhibition rates of Au-SM5-1 NPs, Au-IgG
NPs, IgG, Au NPs, SM5-1 were 38.03% ± 4.35%, 4.77% ± 1.46%,
8.37% ± 1.37%, 6.42% ± 1.05%, 9.39% ± 1.18% respectively on day 30,
shown in Fig. 7F.
In order to further analyze the antitumor efﬁcacy, BLT method
combined micro-computer tomography technology (CT) was used
to reconstruct 3D information of the inner bioluminescence source.
In the process of the reconstruction program, the threshold was
adjusted as 0.65 and the regularization was set to i  1012
(i ¼ 1, 2, 3, 4, 5, 6, 7, 8, 9). The reconstruction results of Au-SM5-1
NPs and Au-IgG NPs based on heterogeneous mice are shown in
Fig. 7B. As there are not obvious differences between Au-IgG NPsand Au NPs, SM5-1, IgG, the reconstruction results of the behind
three groups were not shown in this paper. In order to show the
difference clearly, three planes of the tumor including transverse
slice, coronal slice and sagittal slice were isolated from the 3D
reconstructed data, as shown in Fig. 7C and D. After 3D recon-
struction, we calculated the volume of bioluminescence source of
tumor-bearing mice in each group, the data was shown in Table 2.
The results showed that the inhibition rates of Au-SM5-1 NPs, Au-
IgG NPs, IgG, SM5-1, Au NPs were 39.64% ± 4.87%, 7.98% ± 2.79%,
7.54% ± 2.23%, 6.98% ± 3.12%, 7.56% ± 2.76% respectively. As listed at
the second column in Table 2, the reconstructed tumor volumes
were coincident with the results determined by the abdomen
bioluminescence intensity of orthotopic liver tumor mice.
3.8. The effect of Au-SM5-1 on tumor angiogenesis, apoptosis, and
proliferation
The above study suggested that Au-SM5-1 NPs inhibited tumor
proliferation and induced tumor cell apoptosis. For further veriﬁ-
cation of these results, xenografts of HCC-LM3-fLuc tumor tissues
from PBS, Au NPs, SM5-1, IgG, Au-IgG NPs and Au-SM5-1 NPs on
mice were sliced and stained using the TUNEL assay and KI67 assay
and examined with a ﬂuorescence microscope (results are shown
in Fig. 8). From Fig. 8AeF, the number of apoptotic nuclei (green (in
the web version)) was smaller in Au NPs-, SM5-1-, Au-IgG NPs-,
IgG- and PBS-treated xenografts compared to those in Au-SM5-1
NPs-treated xenografts. Fig. 8GeL showed that the inhibitory ef-
fects of Au-SM5-1 NPs on tumor growth were consistent with the
results of the apoptosis study as revealed by the TUNEL assay.
Angiogenesis is a prerequisite for advanced tumor growth, and
thus, the number of vessels per ﬁeld was counted to evaluate the
anti-angiogenesis efﬁcacy of the drugs (Fig. 8MeR).The quantita-
tive results (Fig. 8M, N) showed that the antitumor activity of Au-
SM5-1 NPs was 40% more effective than PBS. The results showed
that Au-SM5-1 NPs had higher efﬁcacy to down-regulate tumor
angiogenesis than those of the other three groups (Fig. 8SeU). The
Table 2
Reconstruction results of the six groups using the ﬁnite element method based on bioluminescent intensity calibration.
Group Reconstructed tumor volume (mm3) Bioluminescent intensity (106 photons/s/sr)
Au-SM5-1 NPs 49.77 ± 7.55 5.63 ± 0.78
Au-IgG NPs 75.87 ± 7.58 8.69 ± 0.98
Au NPs 76.22 ± 7.67 8.76 ± 0.65
SM5-1 76.69 ± 7.64 8.54 ± 0.37
Control human IgG 76.23 ± 7.71 8.66 ± 0.82
Control 82.45 ± 7.89 9.45 ± 1.23
Fig. 8. Immunohistochemistry analysis of tumor cell apoptosis, cell proliferation, and angiogenesis at 15 days post-treatment after PBS (A, G, M), Au NPs (B, H, N), SM5-1 (C, I, O),
Au-SM5-1 NPs (D, J, P), Au-IgG NPs (E, K, Q), control human IgG (F, L, R) treatment. S, T, and U are the quantitative results of cell apoptosis, proliferation, and angiogenesis,
respectively. (**p < 0.01).
X. Ma et al. / Biomaterials 87 (2016) 46e5654antitumor efﬁcacy of Au NPs and SM5-1 was far worse than Au-
SM5-1 NPs treated group because of the lower accumulation of
Au NP and SM5-1 compared to Au-SM5-1 NPs. Similarly, Au-IgG
NPs and IgG can hardly inhibit the tumor growth too. Thus, all
these data demonstrated that Au-SM5-1 NPs had the highest
antitumor efﬁcacy, whereas the antitumor efﬁcacies of Au NPs, Au-
IgG NPs, IgG and SM5-1 groups were a bit higher to the PBS treated
group.
4. Discussion
HCC is a type of liver cancer found in the world with a high
incidence and high death rate [1,2]. Previous studies have shown
that SM5-1 can inhibit Ch-Hep-3 tumor cell proliferation [18]. Here,
we prepared SM5-1-conjugated Au NPs and investigated their
enhanced efﬁcacy of cell proliferation inhibition in the HCC-LM3
cells and tumor reduction in xenograft nude mouse model. Au-SM5-1 NPs showed improved antitumor efﬁcacy compared with
untreated and SM5-1 alone both in vitro and in vivo, this may be
achieved through the following biological characteristics.
First of all, passive transport function of Au NPs delivered Au-
SM5-1 NPs to surrounding of the tumor cells with diminished
immune clearance [27]. This may due to lackness of a thymus for
nude mice. They cannot generate mature T lymphocytes. Therefore
they are unable to mount adaptive immune responses [16]. Another
reason for this passive transportation may be that the targeted
nanoparticles are designed to bind to SM5-1 binding protein on
HCC cells, thus possible delaying clearance from the site of the
tumor [14]. Sodium azide, b-cycloamylose and amiloride are the
inhibitory agent of clathrin-dependent endocytosis, macro-
pinocytosis endocytosis and caveolin-dependent pathways
respectively. For Au-SM5-1 NPs group, sodium azide, b-cyclo-
amylose and amiloride can inhibit 39.3%, 11.8% and 22.5% cell up-
take respectively. The results proved that enhanced clathrin-
X. Ma et al. / Biomaterials 87 (2016) 46e56 55dependent endocytosis as well as the binding afﬁnity of antibody-
receptor increased the concentration of Au-SM5-1 NPs which
resulted in improving anti-proliferative effect [56]. In addition, Au
NPs can prolong the retention time of the drugs in the tumor. This
will increase the probability of endocytosis, resulting in an
increased cell proliferation inhibition rate.
After endocytosis, Au-SM5-1 NPs obviously inhibited the cell
proliferation and induced cell apoptosis through regulating some
genes. To study the mechanisms, Genechip technology has been
used to identify associated genes and to evaluate their expression
levels under various conditions [57e63]. Then, bioinformatics was
employed to analyze functions and pathways of differential
expression genes. Down-regulated DUOX2 and NOX1 can change
the oxidase gene expression level and disturb the dynamic balance
of reactive oxygen species (ROS) enzyme system. They further
inhibit tumor cell proliferation and induce cell apoptosis [53,55]. As
an important negative regulatory factor of cell cycle, gene P21 in-
ﬂuence the activity of cyclin-dependent kinase (CDK) through
competitively binding cyclin B and cyclin E and further inﬂuence
the progress of cell cycle. While the up-regulation of P21 would
lead to cell cycle arrested at G1/S or G2/S.
Additionally, Au-SM5-1 NPs may be accumulated to the tumor
and subsequently inhibits angiogenic which plays a key role in
tumor formation. This effect was examined via bioluminescence
imaging in subcutaneous and orthotopic liver tumor model
[38e41,64e69]. Our results indicated that Au-SM5-1 NPs can
signiﬁcantly inhibit tumor growth in xenograft mouse model.
In summary, we demonstrated the synthesis and characteriza-
tion of SM5-1-conjugated Au NPs for immunotherapy of hepato-
cellular carcinoma. The results indicated that Au-SM5-1 NPs could
efﬁciently inhibit cell proliferation and induce cell apoptosis in
HCC-LM3 cells comparedwith SM5-1 alone both in vitro and in vivo.
It is believed that the conjugation of SM5-1 to Au NPs provides a
potential approach for target therapy of p230 over-expressed can-
cer, such as hepatocellular carcinoma, melanoma and breast cancer.
5. Conclusion
In this study, SM5-1 conjugated Au NPs have been successfully
prepared and applied in the treatment of HCC. Both in vitro and
in vivo results demonstrated that conjugation of SM5-1 and Au NPs
efﬁciently increased the tumor growth inhibition rates in HCC
which overexpressed a membrane protein (p230) with 230-kDa. In
addition, we investigated the tumor growth inhibition efﬁcacy of
Au-SM5-1 NPs for orthotopic liver tumor treatment. The recon-
struction results of 3D information of the inner bioluminescence
source showed that Au-SM5-1 NPs can achieve considerable anti-
tumor efﬁcacy in HCC. In conclusion, our results indicated that Au
NPs conjugated SM5-1 antibody provided a potential therapy
approach for HCC targeted therapy.
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